Evidence map›Paper›PMID 35677069›Full record

ArticlebioRxiv : the preprint server for biology2022

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.

Young-Jun Park, Dora Pinto, Alexandra C Walls, Zhuoming Liu, Anna De Marco, Fabio Benigni, Fabrizia Zatta, Chiara Silacci-Fregni, Jessica Bassi, Kaitlin R Sprouse and 42 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 63 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

52 authors at 9 institutions in 5 countries.

Young-Jun ParkDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Dora PintoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Zhuoming LiuDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Anna De MarcoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Fabio BenigniHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Fabrizia ZattaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Chiara Silacci-FregniHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Jessica BassiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Kaitlin R SprouseDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Amin AddetiaDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
John E BowenDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Cameron StewartDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Martina GiurdanellaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Christian SalibaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Barbara GuarinoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Michael A SchmidHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Nicholas FrankoDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Jennifer LogueDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Ha V DangVir Biotechnology, San Francisco, CA 94158, USA.
Kevin HauserVir Biotechnology, San Francisco, CA 94158, USA.
Julia di IulioVir Biotechnology, San Francisco, CA 94158, USA.
William RiveraVir Biotechnology, San Francisco, CA 94158, USA.
Gretja SchnellVir Biotechnology, San Francisco, CA 94158, USA.
Anushka RajeshVir Biotechnology, San Francisco, CA 94158, USA.
Jiayi ZhouVir Biotechnology, San Francisco, CA 94158, USA.
Nisar FarhatVir Biotechnology, San Francisco, CA 94158, USA.
Hannah KaiserVir Biotechnology, San Francisco, CA 94158, USA.
Martin Montiel-RuizVir Biotechnology, San Francisco, CA 94158, USA.
Julia NoackVir Biotechnology, San Francisco, CA 94158, USA.
Florian A LemppVir Biotechnology, San Francisco, CA 94158, USA.
Javier JanerDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Rana AbdelnabiLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Piet MaesLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Paolo FerrariFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Alessandro CeschiFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Olivier GianniniFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Guilherme Dias de MeloInstitut Pasteur, Université de Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, F-75015, France.
Lauriane KergoatInstitut Pasteur, Université de Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, F-75015, France.
Hervé BourhyInstitut Pasteur, Université de Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, F-75015, France.
Johan NeytsLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Leah SoriagaVir Biotechnology, San Francisco, CA 94158, USA.
Lisa A PurcellVir Biotechnology, San Francisco, CA 94158, USA.
Gyorgy SnellVir Biotechnology, San Francisco, CA 94158, USA.
Sean P J WhelanDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Antonio LanzavecchiaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Herbert W VirginVir Biotechnology, San Francisco, CA 94158, USA.
Luca PiccoliHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Helen ChuDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Matteo Samuele PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
VIR Biotechnology (United States) · USVir Biotechnology (Switzerland) · CHUniversity of Washington · USWashington University in St. Louis · USHoward Hughes Medical Institute · USInstitut Pasteur · FRRega Institute for Medical Research · BEEnte Ospedaliero Cantonale · CHUNSW Sydney · AU

Funding

Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
Mechanism and Inhibition of SARS-CoV-2 EntryR01AI163019 · NIAID · WASHINGTON UNIVERSITY · PI KIRCHHAUSEN, TOMAS, WHELAN, SEAN PJ · 2021 to 2025
$3.8M
NIAID NIH HHS DP1 AI158186NIAID NIH HHS HHSN272201700059CNIAID NIH HHS R01 AI163019
6 · The paper itself

Abstract

SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA.2 and that breakthrough infections, but not vaccination-only, induce neutralizing activity in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1 and BA.2 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity. While most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant antibody, that is unaffected by any Omicron lineage spike mutations and is a strong candidate for clinical development.

Identifiers

PMID35677069
PMCPMC9176643
OpenAlexW4280530681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.